Modulating Pharmacokinetics, Tumor Uptake and Biodistribution by Engineered Nanoparticles

Rochelle R. Arvizo, Oscar R. Miranda, Daniel F. Moyano, Chad A. Walden, Karuna Giri, Resham Bhattacharya, J. David Robertson, Vincent M. Rotello, Joel M. Reid, Priyabrata Mukherjee

PLoS ONE · 2011 · 393 citations · 26 references

DOIFull text

Open access

Concepts

TL;DR

Inorganic nanoparticles are promising tools for biomedical detection, diagnosis, and therapy, yet the impact of surface chemistry on their pharmacokinetics, tumor uptake, and biodistribution remains poorly understood. This study investigates how nanoparticle surface charge influences pharmacokinetics, tumor uptake, and biodistribution. The authors employed a family of structurally homologous nanoparticles with neutral, zwitterionic, negative, and positive surface charges and administered them to normal and athymic mice via tail vein or peritoneal injection. Neutral and zwitterionic nanoparticles exhibited longer circulation times and enhanced tumor uptake via passive targeting, whereas negatively and positively charged particles had shorter half‑lives and reduced tumor accumulation.

Abstract

Background Inorganic nanoparticles provide promising tools for biomedical applications including detection, diagnosis and therapy. While surface properties such as charge are expected to play an important role in their in vivo behavior, very little is known how the surface chemistry of nanoparticles influences their pharmacokinetics, tumor uptake, and biodistribution. Method/Principal Findings Using a family of structurally homologous nanoparticles we have investigated how pharmacological properties including tumor uptake and biodistribution are influenced by surface charge using neutral (TEGOH), zwitterionic (Tzwit), negative (TCOOH) and positive (TTMA) nanoparticles. Nanoparticles were injected into mice (normal and athymic) either in the tail vein or into the peritoneum. Conclusion Neutral and zwitterionic nanoparticles demonstrated longer circulation time via both IP and IV administration, whereas negatively and positively charged nanoparticles possessed relatively short half-lives. These pharmacological characteristics were reflected on the tumor uptake and biodistribution of the respective nanoparticles, with enhanced tumor uptake by neutral and zwitterionic nanoparticles via passive targeting.

References

26